abstract |
Described are compounds of formula I Formula I It finds utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders via inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinase. These compounds also find utility in the treatment of c-FMS, c-KIT, or other mammalian diseases mediated by PDGFR kinase. |